Identification

Name
Risperidone
Accession Number
DB00734  (APRD00187)
Type
Small Molecule
Groups
Approved, Investigational
Description

Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [11, 12].

Risperidone inhibits dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. It is also said to block histamine receptors, and other neural receptors which are currently being studied [12, 3].

Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors [11, 12, 3].

Structure
Thumb
Synonyms
  • risperdone
  • Risperidona
  • Risperidonum
  • Risperin
  • Rispolept
  • Rispolin
  • Sequinan
External IDs
N05AX08 / R-64,766 / R-64766 / RCN-3028 / RCN3028
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act RisperidoneTablet1 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet3 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet0.5 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet0.25 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet2 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Act RisperidoneTablet4 mgOralActavis Pharma Company2006-07-05Not applicableCanada
Q-risperidoneTablet0.25 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet2 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet4 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidoneTablet1 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ag-risperidoneTablet0.25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet4.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet1.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet3.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet0.50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidoneTablet2.0 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-risperidoneTablet3.0 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneSolution1 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet0.50 mgOralApotex Corporation2006-07-05Not applicableCanada
Apo-risperidoneTablet2.0 mgOralApotex Corporation2006-07-05Not applicableCanada
International/Other Brands
Risperdal / Risperidal M-Tab (Janssen) / Risperin (Gador) / Rispolept / Rispolin / Sequinan
Categories
UNII
L6UH7ZF8HC
CAS number
106266-06-2
Weight
Average: 410.4845
Monoisotopic: 410.211804333
Chemical Formula
C23H27FN4O2
InChI Key
RAPZEAPATHNIPO-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1

Pharmacology

Indication

Risperidone belongs to the class of medications known as ​second generation atypical antipsychotics [2, 3, 12]. It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [3, 4, 11, 12].

Associated Conditions
Pharmacodynamics

The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders [3, 4, 11].

Risperidone has high affinity binding to serotonergic 5-HT2A receptors versus dopaminergic D2 receptors in the brain [2, 3]. Risperidone binds the D2 receptors with lower affinity than the traditional, first generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms in Risperidone use is attributed to its moderate affinity for dopaminergic D2 receptors [7, 11, 5].

Mechanism of action

Though its mechanism of action is not fully understood at this time, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively [3, 4, 5].

D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations. Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect [7, 10]. Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors [6, 7]. Low affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided [6, 7, 8].

Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation [11, 12]. The high affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is
therefore not completely inhibited [5, 7]. Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms.

Risperidone has also been said to be an antagonist of alpha-1 (α1) alpha-2 (α2) receptors, and histamine (H1) receptors [11]. Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time [11, 12].

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 7Not AvailableHuman
Absorption

Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.

Volume of distribution

1 to 2 L/kg

Protein binding

Risperidone, ~88% bound in human plasma; 9-hydroxyrisperidone, ~77% bound in human plasma [9].

Metabolism

Extensively metabolized by hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone, which has approximately the same receptor binding affinity as risperidone [6, 9]. Hydroxylation is dependent on debrisoquine 4-hydroxylase and metabolism is sensitive to genetic polymorphisms in debrisoquine 4-hydroxylase [9]. Risperidone also undergoes N-dealkylation to a lesser extent [7, 9].

Route of elimination

Risperidone is extensively metabolized in the liver. In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives are prolonged compared to young healthy subjects [9, 13].

Half life

3 hours in extensive metabolizers [9] Up to 20 hours in poor metabolizers [9]

Clearance

Risperidone is cleared by the kidneys. Clearance is decreased in the elderly and those with renal creatinine clearance of 15 mL/min to 59 mL/min, which decreases clearance by 60% [13].

Toxicity

Symptoms of overdose include lethargy, dystonia/spasm, tachycardia, bradycardia, and seizures. LD50=57.7 mg/kg (rat, oral) and 34 mg/kg (rat, intravenous) [5, 6, 7].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Risperidone.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Risperidone.Investigational
2,5-Dimethoxy-4-ethylamphetamineRisperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineRisperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRisperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineRisperidone may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Risperidone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Risperidone.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Risperidone.Approved, Investigational
AcepromazineRisperidone may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Risperidone can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Risperidone is combined with Adipiplon.Investigational
AdrafinilRisperidone may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineRisperidone may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Risperidone.Experimental, Investigational
AlaproclateThe metabolism of Risperidone can be decreased when combined with Alaproclate.Experimental
AldesleukinAldesleukin may increase the hypotensive activities of Risperidone.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Risperidone.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Risperidone.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Risperidone.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Risperidone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Risperidone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.Approved, Illicit, Investigational
AlprenololRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Risperidone.Approved
AmibegronRisperidone may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineAmifostine may increase the hypotensive activities of Risperidone.Approved, Investigational
AmilorideAmiloride may increase the hypotensive activities of Risperidone.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Risperidone.Illicit, Withdrawn
AmiodaroneAmiodarone may increase the hypotensive activities of Risperidone.Approved, Investigational
AmisulprideRisperidone may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazRisperidone may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineRisperidone may increase the antihypertensive activities of Amitriptyline.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Risperidone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Risperidone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.Approved, Illicit
AmoxapineRisperidone may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Risperidone is combined with Amperozide.Experimental
AmphetamineRisperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BAmphotericin B may increase the hypotensive activities of Risperidone.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Risperidone is combined with Amrinone.Approved
Amyl NitriteAmyl Nitrite may increase the hypotensive activities of Risperidone.Approved
AnagrelideRisperidone may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineRisperidone may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Risperidone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
ApraclonidineApraclonidine may increase the hypotensive activities of Risperidone.Approved
AprepitantThe serum concentration of Risperidone can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Risperidone is combined with Aranidipine.Approved, Investigational
ArbutamineRisperidone may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolRisperidone may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleRisperidone may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypotensive activities of Risperidone.Investigational
Arsenic trioxideArsenic trioxide may increase the hypotensive activities of Risperidone.Approved, Investigational
ArtemetherRisperidone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Articaine.Approved
AsenapineRisperidone may increase the antihypertensive activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Risperidone.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Risperidone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Risperidone.Approved
AtomoxetineThe metabolism of Risperidone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Risperidone is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the hypotensive activities of Risperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Azaperone.Investigational, Vet Approved
AzelastineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Risperidone is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilAzilsartan medoxomil may increase the hypotensive activities of Risperidone.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Risperidone is combined with Azimilide.Investigational
AzithromycinRisperidone may increase the QTc-prolonging activities of Azithromycin.Approved
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Risperidone.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Risperidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Risperidone.Investigational
BambuterolRisperidone may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.Illicit
BarnidipineBarnidipine may increase the hypotensive activities of Risperidone.Approved
BedaquilineRisperidone may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololRisperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Risperidone.Investigational
BenazeprilBenazepril may increase the hypotensive activities of Risperidone.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Risperidone is combined with Bencyclane.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Risperidone.Approved
BenidipineThe risk or severity of hypotension can be increased when Risperidone is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Risperidone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzocaine.Approved, Investigational
BenzphetamineRisperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineRisperidone may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBepridil may increase the hypotensive activities of Risperidone.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Risperidone.Approved, Investigational
BetaxololBetaxolol may increase the hypotensive activities of Risperidone.Approved, Investigational
BevantololRisperidone may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Risperidone is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the hypotensive activities of Risperidone.Approved
BitolterolRisperidone may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe metabolism of Risperidone can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibBortezomib may increase the hypotensive activities of Risperidone.Approved, Investigational
BosentanThe serum concentration of Risperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Risperidone.Approved
BretyliumBretylium may increase the hypotensive activities of Risperidone.Approved
BrexpiprazoleRisperidone may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the hypotensive activities of Risperidone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Risperidone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Risperidone.Investigational, Withdrawn
BufuralolRisperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone.Approved
BunazosinBunazosin may increase the antihypertensive activities of Risperidone.Investigational
BupivacaineBupivacaine may increase the hypotensive activities of Risperidone.Approved, Investigational
BupranololRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Risperidone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Risperidone is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.Approved, Illicit, Vet Approved
ButriptylineButriptyline may decrease the antihypertensive activities of Risperidone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Risperidone.Approved
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Risperidone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Risperidone is combined with Canertinib.Investigational
CaptoprilCaptopril may increase the hypotensive activities of Risperidone.Approved
CarbamazepineThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinCarbetocin may increase the hypotensive activities of Risperidone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Risperidone is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Risperidone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Risperidone is combined with Caroverine.Experimental
CarteololCarteolol may increase the hypotensive activities of Risperidone.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Risperidone.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.Experimental
CelecoxibThe metabolism of Risperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololRisperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Risperidone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Risperidone.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Risperidone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Risperidone can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Risperidone.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine.Approved
ChlorphentermineRisperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Risperidone.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Risperidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Risperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Risperidone.Experimental
CilazaprilCilazapril may increase the hypotensive activities of Risperidone.Approved
CilnidipineCilnidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
CimetidineThe metabolism of Risperidone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Risperidone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Risperidone is combined with Cinnarizine.Approved, Investigational
CiprofloxacinRisperidone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineRisperidone may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideRisperidone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Risperidone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Risperidone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Risperidone can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolRisperidone may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineClevidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.Approved
ClobazamThe metabolism of Risperidone can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineClofarabine may increase the hypotensive activities of Risperidone.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the hypotensive activities of Risperidone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Risperidone is combined with Clopenthixol.Experimental
CloranololRisperidone may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Risperidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the hypotensive activities of Risperidone.Approved
CobicistatThe serum concentration of Risperidone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Risperidone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Risperidone.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Risperidone.Approved, Investigational
CrizotinibThe metabolism of Risperidone can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Risperidone can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Risperidone is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Risperidone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.Approved, Investigational
DapagliflozinDapagliflozin may increase the hypotensive activities of Risperidone.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Risperidone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Risperidone.Investigational
DarifenacinThe metabolism of Risperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Risperidone is combined with Darodipine.Experimental
DarunavirThe serum concentration of Risperidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Risperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Risperidone can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Risperidone.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Risperidone is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the hypotensive activities of Risperidone.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe metabolism of Risperidone can be decreased when combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.Approved
DexmedetomidineDexmedetomidine may increase the hypotensive activities of Risperidone.Approved, Vet Approved
DextroamphetamineRisperidone may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Risperidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Risperidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Risperidone.Experimental
DiclofenamideDiclofenamide may increase the hypotensive activities of Risperidone.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Risperidone is combined with Diethyl ether.Experimental
DiethylpropionRisperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Risperidone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Risperidone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Risperidone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Risperidone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Risperidone.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.Approved
DimetacrineDimetacrine may decrease the antihypertensive activities of Risperidone.Approved, Withdrawn
DinutuximabDinutuximab may increase the hypotensive activities of Risperidone.Approved, Investigational
DiphenhydramineThe metabolism of Risperidone can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.Approved, Illicit
DipivefrinRisperidone may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Risperidone.Approved
DisopyramideRisperidone may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dixyrazine.Experimental
DL-MethylephedrineRisperidone may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineRisperidone may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideRisperidone may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronRisperidone may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineRisperidone may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Risperidone is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Risperidone.Approved
DotarizineThe risk or severity of hypotension can be increased when Risperidone is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the hypotensive activities of Risperidone.Approved
DoxepinRisperidone may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineRisperidone may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Risperidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Risperidone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Illicit
DronedaroneRisperidone may increase the antihypertensive activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Drotebanol.Experimental, Illicit
DroxidopaRisperidone may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Risperidone.Approved, Investigational
DuloxetineThe metabolism of Risperidone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz.Approved, Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.Approved, Investigational
EliglustatRisperidone may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Eltanolone.Investigational
EmpagliflozinEmpagliflozin may increase the hypotensive activities of Risperidone.Approved
EnalaprilEnalapril may increase the hypotensive activities of Risperidone.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Risperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Enflurane.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Risperidone.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.Approved
EpanololRisperidone may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Risperidone is combined with Eperisone.Approved, Investigational
EphedraRisperidone may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineRisperidone may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineRisperidone may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineRisperidone may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneEplerenone may increase the hypotensive activities of Risperidone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Risperidone.Approved
EprosartanEprosartan may increase the hypotensive activities of Risperidone.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Risperidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Risperidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Risperidone.Approved
ErythromycinThe metabolism of Risperidone can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololRisperidone may increase the atrioventricular blocking (AV block) activities of Esatenolol.Experimental
EscitalopramThe metabolism of Risperidone can be decreased when combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the hypotensive activities of Risperidone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.Approved, Investigational
EtafedrineRisperidone may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolRisperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etifoxine.Investigational, Withdrawn
EtilefrineRisperidone may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Risperidone is combined with Etomidate.Approved
EtoperidoneThe metabolism of Risperidone can be decreased when combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Risperidone.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.Approved
FelodipineFelodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Risperidone is combined with Fendiline.Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Risperidone.Approved
FenoterolRisperidone may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Risperidone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fexofenadine.Approved, Investigational
FimasartanFimasartan may increase the hypotensive activities of Risperidone.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Risperidone is combined with Fish oil.Approved, Nutraceutical
FlecainideRisperidone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Risperidone can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Risperidone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Risperidone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Risperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Risperidone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Risperidone.Approved
FluvoxamineThe metabolism of Risperidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolRisperidone may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Risperidone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Risperidone can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Risperidone.Approved
FosphenytoinThe metabolism of Risperidone can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Risperidone is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Risperidone.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Risperidone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Risperidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Risperidone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidRisperidone may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Risperidone is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Risperidone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemifloxacinRisperidone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineRisperidone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Risperidone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Risperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Risperidone is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Risperidone.Approved
GoserelinRisperidone may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronRisperidone may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzRisperidone may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineGuanfacine may increase the hypotensive activities of Risperidone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Risperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Risperidone can be decreased when combined with Haloperidol.Approved
HalothaneHalothane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Risperidone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.Approved
HexoprenalineRisperidone may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineRisperidone may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Risperidone.Approved, Investigational
HydralazineHydralazine may increase the hypotensive activities of Risperidone.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Risperidone.Approved, Vet Approved
HydrocodoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Risperidone.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.Approved, Illicit
HydroxyamphetamineRisperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Risperidone.Approved
IbutilideRisperidone may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Risperidone can be decreased when combined with Idelalisib.Approved
IloperidoneRisperidone may increase the antihypertensive activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Risperidone.Approved, Investigational
ImatinibThe metabolism of Risperidone can be decreased when combined with Imatinib.Approved
ImidaprilImidapril may increase the hypotensive activities of Risperidone.Investigational
ImipramineImipramine may increase the hypotensive activities of Risperidone.Approved
IndacaterolRisperidone may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe metabolism of Risperidone can be decreased when combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Risperidone.Approved
IndenololRisperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Risperidone can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Risperidone is combined with Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Risperidone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Risperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Risperidone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Risperidone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Risperidone.Approved, Investigational
Iofetamine I-123Risperidone may decrease the stimulatory activities of Iofetamine I-123.Approved
IprindoleIprindole may decrease the antihypertensive activities of Risperidone.Experimental
IrbesartanIrbesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
IsavuconazoleThe serum concentration of Risperidone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Risperidone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Risperidone can be increased when used in combination with Isocarboxazid.Approved
IsoetarineRisperidone may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
IsomethepteneRisperidone may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Risperidone can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineRisperidone may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.Approved, Investigational
Isosorbide MononitrateIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.Approved
IsoxsuprineIsoxsuprine may increase the hypotensive activities of Risperidone.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Risperidone.Approved, Investigational
ItraconazoleThe metabolism of Risperidone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Risperidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Risperidone can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Risperidone.Approved, Nutraceutical, Withdrawn
LabetalolLabetalol may increase the hypotensive activities of Risperidone.Approved
LacidipineLacidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.Approved, Investigational
LandiololRisperidone may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LenvatinibRisperidone may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
LeuprolideRisperidone may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.Approved, Investigational
LevobetaxololRisperidone may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.Approved, Investigational
LevobunololLevobunolol may increase the hypotensive activities of Risperidone.Approved
LevobupivacaineLevobupivacaine may increase the hypotensive activities of Risperidone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocetirizine.Approved
LevodopaLevodopa may increase the hypotensive activities of Risperidone.Approved
LevofloxacinRisperidone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Risperidone can be decreased when combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.Approved
LevosalbutamolRisperidone may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanLevosimendan may increase the hypotensive activities of Risperidone.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Risperidone is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Risperidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Risperidone.Approved
LisdexamfetamineRisperidone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Risperidone.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Risperidone.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Risperidone.Experimental
LofexidineLofexidine may increase the hypotensive activities of Risperidone.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Risperidone is combined with Loperamide.Approved
LopinavirThe metabolism of Risperidone can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.Approved
LorcaserinThe metabolism of Risperidone can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Risperidone can be increased when it is combined with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Risperidone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Risperidone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.Approved
LuliconazoleThe serum concentration of Risperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Risperidone can be increased when combined with Lumacaftor.Approved
LumefantrineRisperidone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Risperidone.Illicit, Investigational, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Risperidone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Risperidone can be decreased when combined with Manidipine.Approved, Investigational
MannitolMannitol may increase the hypotensive activities of Risperidone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Risperidone is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Risperidone.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Risperidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenMelitracen may decrease the antihypertensive activities of Risperidone.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Risperidone is combined with Menthol.Approved
MephedroneRisperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineRisperidone may decrease the stimulatory activities of Mephentermine.Approved
MepindololRisperidone may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Risperidone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Risperidone is combined with Meptazinol.Experimental
MequitazineRisperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.Approved, Investigational
MetaraminolRisperidone may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Risperidone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.Approved
MethadoneThe metabolism of Risperidone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineRisperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideMethazolamide may increase the hypotensive activities of Risperidone.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.Approved
MethotrimeprazineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineRisperidone may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineRisperidone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Risperidone.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Risperidone.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Risperidone.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Risperidone.Approved
MetipranololMetipranolol may increase the hypotensive activities of Risperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Risperidone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Risperidone.Approved, Investigational
MetyrosineRisperidone may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Risperidone.Experimental
MianserinThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Risperidone is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Risperidone.Approved, Illicit
MidodrineRisperidone may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineRisperidone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Risperidone can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Risperidone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Risperidone.Approved
MilnacipranThe metabolism of Risperidone can be decreased when combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Risperidone.Approved, Investigational
MirabegronThe metabolism of Risperidone can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Risperidone.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Risperidone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Risperidone.Approved, Investigational
MitotaneThe serum concentration of Risperidone can be decreased when it is combined with Mitotane.Approved
MMDARisperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Risperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.Approved
MorphineMorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
MoxifloxacinRisperidone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Risperidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Risperidone.Approved
NaftopidilThe risk or severity of hypotension can be increased when Risperidone is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.Approved
NaphazolineRisperidone may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Risperidone.Approved, Investigational
NebivololNebivolol may increase the hypotensive activities of Risperidone.Approved, Investigational
NefazodoneThe metabolism of Risperidone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Risperidone can be decreased when combined with Nelfinavir.Approved
NesiritideNesiritide may increase the hypotensive activities of Risperidone.Approved, Investigational
NetupitantThe serum concentration of Risperidone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Risperidone can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the hypotensive activities of Risperidone.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Risperidone.Approved, Investigational
NifedipineNifedipine may increase the hypotensive activities of Risperidone.Approved
NiguldipineRisperidone may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibRisperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Risperidone is combined with Niludipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Risperidone.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Risperidone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Risperidone.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Risperidone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrazepam.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Risperidone.Approved, Investigational
Nitric OxideNitric Oxide may increase the hypotensive activities of Risperidone.Approved
NitroglycerinNitroglycerin may increase the hypotensive activities of Risperidone.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Risperidone.Approved, Investigational
Nitrous acidNitrous acid may increase the hypotensive activities of Risperidone.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Nordazepam.Approved
NorepinephrineRisperidone may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineRisperidone may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Normethadone.Approved, Illicit
NortriptylineRisperidone may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinRisperidone may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabObinutuzumab may increase the hypotensive activities of Risperidone.Approved, Investigational
OctopamineRisperidone may decrease the vasoconstricting activities of Octopamine.Experimental
OfloxacinRisperidone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineRisperidone may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Risperidone can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Risperidone.Approved, Investigational
OlodaterolRisperidone may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Risperidone is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Risperidone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Risperidone is combined with Opium.Approved, Illicit
OrciprenalineRisperidone may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Risperidone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Risperidone is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.Approved
OxprenololOxprenolol may increase the hypotensive activities of Risperidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.Approved, Illicit, Investigational
OxyfedrineRisperidone may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineRisperidone may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelPaclitaxel may increase the hypotensive activities of Risperidone.Approved, Vet Approved
PalbociclibThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Risperidone can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverinePapaverine may increase the hypotensive activities of Risperidone.Approved, Investigational
ParaldehydeRisperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Risperidone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibRisperidone may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the hypotensive activities of Risperidone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Risperidone is combined with Penfluridol.Experimental
PentamidineRisperidone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.Approved, Vet Approved
PentobarbitalThe metabolism of Risperidone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Risperidone.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Perazine.Approved, Investigational
PerflutrenRisperidone may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Risperidone.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Risperidone.Approved
PerospironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenazocine.Experimental
PhendimetrazineRisperidone may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Risperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Risperidone.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Risperidone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Risperidone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenoxyethanol.Approved
PhentermineRisperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Risperidone.Approved
PhenylephrineRisperidone may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineRisperidone may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Risperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideRisperidone may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Risperidone is combined with Pinaverium.Approved
PindololPindolol may increase the hypotensive activities of Risperidone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
PipamperonePipamperone may increase the hypotensive activities of Risperidone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.Approved, Investigational
PirbuterolRisperidone may decrease the vasoconstricting activities of Pirbuterol.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Risperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Risperidone is combined with Piritramide.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Risperidone.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Risperidone.Approved, Investigational
PizotifenRisperidone may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorRisperidone may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Risperidone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleRisperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Risperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Risperidone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Risperidone.Approved
PregabalinThe therapeutic efficacy of Risperidone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolRisperidone may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Risperidone is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Prilocaine.Approved
PrimaquineRisperidone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Risperidone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideRisperidone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone.Approved, Investigational
ProcaterolRisperidone may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.Approved, Vet Approved
PromazinePromazine may increase the antihypertensive activities of Risperidone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Promethazine.Approved, Investigational
PropafenoneRisperidone may increase the atrioventricular blocking (AV block) activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Risperidone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.Approved, Vet Approved
PropericiazineRisperidone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineRisperidone may increase the antihypertensive activities of Propiomazine.Approved
PropiverineRisperidone may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Propoxycaine.Approved
PropranololPropranolol may increase the hypotensive activities of Risperidone.Approved, Investigational
ProtokylolRisperidone may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may decrease the antihypertensive activities of Risperidone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Risperidone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Risperidone is combined with PSD502.Investigational
PseudoephedrineRisperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.Approved, Illicit
QuetiapineQuetiapine may increase the hypotensive activities of Risperidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Risperidone.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of Risperidone.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Risperidone.Approved
QuinidineRisperidone may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineRisperidone may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Quinisocaine.Experimental
RacepinephrineRisperidone may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Raclopride.Investigational
RactopamineRisperidone may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Risperidone.Approved
RanolazineThe metabolism of Risperidone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Risperidone.Approved
RemifentanilRemifentanil may increase the hypotensive activities of Risperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Risperidone.Approved, Investigational
ReproterolRisperidone may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineReserpine may increase the hypotensive activities of Risperidone.Approved, Investigational
RifabutinThe metabolism of Risperidone can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Risperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Risperidone can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineRisperidone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Risperidone.Approved
RimiterolRisperidone may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatRiociguat may increase the hypotensive activities of Risperidone.Approved
RitanserinThe risk or severity of adverse effects can be increased when Risperidone is combined with Ritanserin.Investigational
RitobegronRisperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineRisperidone may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Risperidone can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Risperidone.Approved
RolapitantThe metabolism of Risperidone can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Romifidine.Vet Approved
RopiniroleRisperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the hypotensive activities of Risperidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Risperidone.Approved
RotigotineRisperidone may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Risperidone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Risperidone.Approved
SacubitrilSacubitril may increase the hypotensive activities of Risperidone.Approved
SalbutamolRisperidone may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolRisperidone may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe metabolism of Risperidone can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Risperidone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Risperidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Risperidone.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Risperidone is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Risperidone can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the hypotensive activities of Risperidone.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Risperidone.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Risperidone.Approved
SiltuximabThe serum concentration of Risperidone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Risperidone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Risperidone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
SolabegronRisperidone may decrease the vasoconstricting activities of Solabegron.Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Risperidone.Investigational
SotalolSotalol may increase the hypotensive activities of Risperidone.Approved
SpironolactoneSpironolactone may increase the hypotensive activities of Risperidone.Approved
St. John's WortThe serum concentration of Risperidone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Risperidone can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the hypotensive activities of Risperidone.Approved, Investigational
SufentanilSufentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
SulfisoxazoleThe metabolism of Risperidone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.Approved, Investigational
SulpirideRisperidone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Risperidone.Approved, Investigational
SuvorexantRisperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineRisperidone may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Risperidone.Approved, Investigational
TalinololRisperidone may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Risperidone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Risperidone.Approved
TelaprevirThe metabolism of Risperidone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinRisperidone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Risperidone can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Risperidone.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.Approved, Investigational
TerazosinTerazosin may increase the hypotensive activities of Risperidone.Approved
TerbinafineThe metabolism of Risperidone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineRisperidone may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Risperidone.Experimental
TerodilineThe risk or severity of hypotension can be increased when Risperidone is combined with Terodiline.Experimental
TertatololRisperidone may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrodotoxin.Investigational
TetryzolineRisperidone may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideRisperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Risperidone.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiopental.Approved, Vet Approved
ThioproperazineRisperidone may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Risperidone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.Approved, Investigational
TianeptineTianeptine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Risperidone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tilidine.Experimental
TimololTimolol may increase the hypotensive activities of Risperidone.Approved
TipranavirThe metabolism of Risperidone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Risperidone.Approved, Investigational
TocilizumabThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Risperidone.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.Approved, Investigational
TolcaponeTolcapone may increase the hypotensive activities of Risperidone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Risperidone is combined with Tolfenamic Acid.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Risperidone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.Approved
ToremifeneRisperidone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Risperidone.Approved
TranilastThe risk or severity of hypotension can be increased when Risperidone is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Risperidone.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Risperidone.Approved, Investigational
TretinoinTretinoin may increase the hypotensive activities of Risperidone.Approved, Investigational, Nutraceutical
TretoquinolRisperidone may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneTriamterene may increase the hypotensive activities of Risperidone.Approved
TriazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Risperidone is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Risperidone.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trichloroethylene.Approved
TrifluoperazineRisperidone may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Risperidone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Risperidone.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Risperidone is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Risperidone is combined with Trimethadione.Approved
TrimipramineRisperidone may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Risperidone.Investigational, Withdrawn
TulobuterolRisperidone may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Risperidone.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Risperidone.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Risperidone.Approved, Investigational
VandetanibRisperidone may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Risperidone.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Risperidone.Approved
VenlafaxineThe metabolism of Risperidone can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Veralipride.Experimental
VerapamilThe serum concentration of Risperidone can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Risperidone is combined with Vigabatrin.Approved
VilanterolRisperidone may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Risperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Risperidone.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Risperidone is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Risperidone is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Risperidone.Approved, Investigational
VoriconazoleThe metabolism of Risperidone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Risperidone is combined with WIN 55212-2.Experimental
XamoterolRisperidone may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Risperidone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Xylazine.Vet Approved
XylometazolineRisperidone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.Approved
ZimelidineThe metabolism of Risperidone can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Risperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone.Approved, Investigational
ZolpidemRisperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Risperidone is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolRisperidone may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US4804663
General References
  1. Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-6. [PubMed:16004936]
  2. Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64. [PubMed:19113797]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  4. Kemp DE, Canan F, Goldstein BI, McIntyre RS: Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther. 2009 Jun;26(6):588-99. doi: 10.1007/s12325-009-0039-0. Epub 2009 Jun 26. [PubMed:19562274]
  5. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006 Jun;26(6):748-58. [PubMed:16716128]
  6. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  7. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3(6):356-61. [PubMed:14610521]
  8. Acri AA, Henretig FM: Effects of risperidone in overdose. Am J Emerg Med. 1998 Sep;16(5):498-501. [PubMed:9725965]
  9. Mannens G, Meuldermans W, Snoeck E, Heykants J: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994 May;114(4):566-72. [PubMed:7531854]
  10. Hall H, Halldin C, Nyberg S, Farde L, Sedvall G: Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur Neuropsychopharmacol. 1995 Mar;5(1):19-25. [PubMed:7542051]
  11. Atypicality of antipsychotics: A concept re-examined and re-defined [Link]
  12. Risperidone in the Treatment of Schizophrenia [Link]
  13. Pharmacokinetics of Risperidone: Clinical Summary [Link]
External Links
Human Metabolome Database
HMDB0005020
KEGG Drug
D00426
PubChem Compound
5073
PubChem Substance
46505850
ChemSpider
4895
BindingDB
50001885
ChEBI
8871
ChEMBL
CHEMBL85
Therapeutic Targets Database
DAP000003
PharmGKB
PA451257
IUPHAR
96
Guide to Pharmacology
GtP Drug Page
HET
8NU
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Risperidone
ATC Codes
N05AX08 — Risperidone
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (2.54 MB)
MSDS
Download (25.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers5
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherAntipsychotics / Immunoassay1
1CompletedTreatmentBipolar Disorder (BD)1
1CompletedTreatmentChild Development Disorders, Pervasive1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders4
1CompletedTreatmentSchizophrenic Disorders7
1TerminatedDiagnosticSchizophrenic Disorders1
1Unknown StatusNot AvailableHealthy Volunteers / Pharmacogenetics1
1Unknown StatusTreatmentCocaine-Related Disorders1
1, 2CompletedBasic ScienceSchizotypal Personality Disorder1
1, 2CompletedTreatmentChild Development Disorders, Pervasive1
1, 2CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
1, 2CompletedTreatmentSubjects Had Unipolar, Non-psychotic Major Depression1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
1, 2WithdrawnTreatmentSchizophrenic Disorders1
2CompletedPreventionHealthy Volunteers1
2CompletedTreatmentAlcoholism / Dual Diagnosis / Schizophrenic Disorders1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentChronic Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentCocaine-Related Disorders3
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders2
2CompletedTreatmentDementias1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentEfficacy / Iloperidone / Schizophrenic Disorders1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2CompletedTreatmentPost-Traumatic / Stress Disorders1
2CompletedTreatmentSchizophrenia, Acute Episode1
2CompletedTreatmentSchizophrenic Disorders12
2Not Yet RecruitingTreatmentSchizophrenic Disorders1
2RecruitingTreatmentMenopausal Hot Flushes / Premenstrual Syndrome1
2RecruitingTreatmentTreatment-resistant Schizophrenia1
2TerminatedTreatmentCocaine-Related Disorders2
2TerminatedTreatmentMajor Depressive Disorder With Panic Attacks / Panic Disorders1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2Unknown StatusTreatmentSchizophrenic Disorders1
2WithdrawnTreatmentSchizophrenic Disorders1
2, 3CompletedTreatmentAutism, Early Infantile1
2, 3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2, 3CompletedTreatmentSchizophrenic Disorders3
2, 3TerminatedTreatmentCognitive Effect on Schizophrenic Patients / Schizophrenic Disorders1
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3WithdrawnTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedNot AvailableBipolar Disorder (BD)1
3CompletedDiagnosticAdjustment Disorder / Attention Deficit Disorder With Hyperactivity (ADHD) / Bipolar Disorder (BD) / Impulse Control Disorders / Intermittent Explosive Disorder / Oppositional Defiant Disorder / Pervasive Developmental Disorder NOS1
3CompletedPreventionBipolar Disorder (BD)1
3CompletedPreventionSchizophrenic Disorders1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias3
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Psychiatric Disorder NOS1
3CompletedTreatmentAnxiety Disorders1
3CompletedTreatmentAnxiety Disorders / Bipolar Disorder (BD)1
3CompletedTreatmentAsperger's Syndrome / Autistic Disorder / DCild Development Disorders, Pervasive / Developmental Disability / Rett's Syndrome1
3CompletedTreatmentAttention Deficit and Disruptive Behavior Disorders1
3CompletedTreatmentAutistic Disorder1
3CompletedTreatmentAutistic Disorder in Children and Adolescents1
3CompletedTreatmentBipolar Disorder (BD)6
3CompletedTreatmentBipolar Disorder (BD) / Manic Disorder3
3CompletedTreatmentAcute Manic episode / Bipolar Disorder (BD)2
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentCessation, Smoking / Schizophrenic Disorders1
3CompletedTreatmentChild Behavior Disorders / Learning Disorders1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression / Schizophrenic Disorders1
3CompletedTreatmentDevelopmental Delay Disorders / Mental Retardation1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentMental Health / Psychiatric Disorder NOS / Psychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentOppositional Defiant Disorder3
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders8
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders18
3RecruitingTreatmentAnxiety States1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3RecruitingTreatmentSchizophrenic Disorders2
3TerminatedTreatmentAlzheimer's Disease (AD) / Dementias1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar I Disorder / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentMajor Depression With Psychotic Features1
3TerminatedTreatmentSchizophrenic Disorders3
3Unknown StatusNot AvailableSchizoaffective Disorders1
3Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
3Unknown StatusTreatmentPsychosis Nos/Other1
3Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3WithdrawnTreatmentSchizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizophrenic Disorders1
4CompletedNot AvailableAntipsychotic Agents / Physiological Effects of Drugs / Psychiatric Disorder NOS / Psychotropic Drugs / Schizophrenic Disorders / Therapeutic Uses / Tranquilizing Agents1
4CompletedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedNot AvailableSchizophrenic Disorders2
4CompletedBasic ScienceHealthy Volunteers / Schizophrenic Disorders1
4CompletedPreventionPost-Traumatic Stress Disorder (PTSD)1
4CompletedPreventionSchizophrenic Disorders2
4CompletedSupportive CareAutistic Disorder1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Agitation / Aggressive Behavior / Alzheimer's Disease (AD) / Psychotic Disorder NOS1
4CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD) / Psychosis1
4CompletedTreatmentAggressive Behavior1
4CompletedTreatmentAggressive Behavior / Attention Deficit Disorder With Hyperactivity (ADHD) / Attention Deficit-Hyperactivity / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD / Pervasive Development Disorders1
4CompletedTreatmentAlcohol Abuse / Psychotic Disorder NOS / Schizophrenic Disorders / Substance Abuse1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnorexia Nervosa (AN)1
4CompletedTreatmentAnxiety Disorders / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentAsperger's Disorder1
4CompletedTreatmentAutism, Early Infantile / Autistic Disorder1
4CompletedTreatmentAutistic Disorder / Bipolar Disorder (BD) / Conduct and Other Disruptive Behavior Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)6
4CompletedTreatmentBipolar Disorder (BD) / Generalized Anxiety Disorder (GAD) / Panic Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentCannabis Abuse / Cannabis Dependence / Dual Diagnosis / Schizophrenic Disorders1
4CompletedTreatmentDementias2
4CompletedTreatmentDepression, Bipolar / Substance Abuse1
4CompletedTreatmentDiabetes Mellitus (DM) / Hyperglycemias / Metabolic Syndromes / Schizophrenic Disorders1
4CompletedTreatmentDiabetes Mellitus (DM) / Schizophrenic Disorders1
4CompletedTreatmentEmergency Treatment / Psychotic Disorder NOS / Schizophrenic Disorders1
4CompletedTreatmentExtrapyramidal Syndrome / Schizophrenic Disorders1
4CompletedTreatmentHyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentMethamphetamine Dependence1
4CompletedTreatmentNegative Symptoms / Schizophrenic Disorders1
4CompletedTreatmentNeuroleptic-Induced Tardive Dyskinesia1
4CompletedTreatmentPsychosis, Schizophrenia1
4CompletedTreatmentPsychosis / Schizophrenic Disorders1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders2
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders8
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder2
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Substance Abuse / Substance Dependence1
4CompletedTreatmentSchizophrenia, Schizoaffective Disorder1
4CompletedTreatmentSchizophrenic Disorders27
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4Enrolling by InvitationTreatmentPsychosis / Psychotic Disorder NOS / Schizophrenic Disorders1
4Enrolling by InvitationTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4Not Yet RecruitingTreatmentSchizophrenic Disorders2
4RecruitingBasic ScienceSchizophrenia Spectrum and Other Psychotic Disorders1
4RecruitingDiagnosticFirst Episode Psychosis / Schizoaffective Disorders / Schizophrenic Disorders1
4RecruitingDiagnosticFragile X Syndrome (FXS) / Velocardiofacial Syndrome / Williams Syndrome1
4RecruitingTreatmentBipolar Disorder (BD)1
4RecruitingTreatmentSchizophrenia (Recent-onset)1
4RecruitingTreatmentSchizophrenic Disorders1
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedNot AvailableSchizophrenic Disorders1
4TerminatedBasic ScienceSchizophrenic Disorders1
4TerminatedPreventionSchizophrenic Disorders1
4TerminatedTreatmentAcute Agitation / Delirium1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentMethamphetamine Dependence1
4TerminatedTreatmentSchizophrenic Disorders7
4Unknown StatusDiagnosticSchizophrenic Disorders1
4Unknown StatusTreatmentAttention Deficit Disorder With Hyperactivity1
4Unknown StatusTreatmentAttention Deficit/Hyperactivity Disorder / Oppositional Defiant Disorder1
4Unknown StatusTreatmentDelirium1
4Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4Unknown StatusTreatmentSchizophrenia, First-Episode1
4Unknown StatusTreatmentSchizophrenic Disorders4
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentTreatment Resistant Depression (TRD)1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedNot AvailablePatients Already Taking Risperidone for Clinical Indications1
Not AvailableCompletedBasic ScienceImaging of the Brain and Antipsychotics / Neuronal Network Changes1
Not AvailableCompletedBasic ScienceSchizophrenic Disorders1
Not AvailableCompletedDiagnosticProdromal Schizophrenia / Psychotic Disorder NOS1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedHealth Services ResearchPsychomotor Agitation / Sleep Disorders, Circadian Rhythm / Sleeplessness1
Not AvailableCompletedScreeningBMI >30 kg/m2 / Diabetes Mellitus (DM) / Metabolic Syndromes1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedTreatmentAutistic Disorder1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Bipolar I / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine / Methamphetamine Dependence1
Not AvailableCompletedTreatmentCannabis-Related Disorder / Psychotic Disorder NOS / Schizophrenic Disorders / Substance-Related Disorders1
Not AvailableCompletedTreatmentChild Development Disorders, Pervasive1
Not AvailableCompletedTreatmentDelusional Disorder / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableCompletedTreatmentMajor Depression With Panic Attacks / Panic Disorders1
Not AvailableCompletedTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders3
Not AvailableCompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentSchizotypal Personality Disorder1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingNot AvailableWeight, Body1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAdverse Drug Effect of Antipsychotics and Neuroleptics / Efficacy / Individualed Opitmal Therapy / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / First-Episode Psychosis1
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailablePsychosis / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailablePsychotic Disorder NOS1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableRecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableRecruitingTreatmentSchizophrenic Disorders1
Not AvailableSuspendedTreatmentPsychotic Disorder Not Otherwise Specified / Schizoaffective Disorders / Schizophrenic Disorders / Severe Bipolar Disorder With Psychotic Features1
Not AvailableTerminatedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
Not AvailableTerminatedNot AvailableSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableTerminatedBasic ScienceSchizophrenic Disorders1
Not AvailableTerminatedOtherBipolar Disorder (BD)1
Not AvailableTerminatedTreatmentAggressive Behavior / Psychosis1
Not AvailableUnknown StatusNot AvailableSchizophrenic Disorders1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentBorderlone Personality Disorder1
Not AvailableUnknown StatusTreatmentCannabis Dependence / Psychostimulant Dependence1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableUnknown StatusTreatmentSevere Mood Dysregulation1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnTreatmentActive Suicidal Ideations / Depression / Impulsivity1
Not AvailableWithdrawnTreatmentPsychosis Not Otherwise Specified (NOS) / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform1

Pharmacoeconomics

Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Ortho mcneil janssen pharmaceutical inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Precision dose inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Par pharmaceutical inc
  • Ranbaxy laboratories inc
  • Sandoz inc
  • Zydus pharmaceuticals usa inc
  • Actavis totowa llc
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ratiopharm
  • Synthon pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceuticals corp
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Cadila Healthcare Ltd.
  • Cardinal Health
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Core Pharmaceuticals
  • Dept Health Central Pharmacy
  • DispenseXpress Inc.
  • Doctor Reddys Laboratories Ltd.
  • Greenstone LLC
  • Hikma Pharmaceuticals
  • Janssen-Ortho Inc.
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • Nutritional Research Association Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Par Pharmaceuticals
  • Patriot Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Quality Care
  • Ratiopharm Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vintage Pharmaceuticals Inc.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral0.50 mg
Tablet, orally disintegratingOral0.5 mg
TabletOral1.0 mg
TabletOral2.0 mg
TabletOral3.0 mg
TabletOral4.0 mg
Tablet, orally disintegratingOral1 mg
Tablet, orally disintegratingOral2 mg
Tablet, orally disintegratingOral3 mg
Tablet, orally disintegratingOral4 mg
TabletOral0.25 mg
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
TabletOral3 mg
TabletOral4 mg
TabletOral5 mg
Injection, powder, for suspension, extended release; kitIntramuscular12.5 mg
Injection, powder, for suspension, extended release; kitIntramuscular25 mg
Injection, powder, for suspension, extended release; kitIntramuscular37.5 mg
Injection, powder, for suspension, extended release; kitIntramuscular50 mg
Kit
SolutionOral1 mg
SolutionOral1 mg/mL
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral0.25 mg/1
TabletOral0.5 mg/1
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral3 mg/1
TabletOral4 mg/1
Tablet, coatedOral.25 mg/1
Tablet, coatedOral.5 mg/1
Tablet, coatedOral1 mg/1
Tablet, coatedOral2 mg/1
Tablet, coatedOral3 mg/1
Tablet, coatedOral4 mg/1
Tablet, film coatedOral.25 mg/1
Tablet, film coatedOral.5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral3 mg/1
Tablet, film coatedOral4 mg/1
Tablet, orally disintegratingOral.25 mg/1
Tablet, orally disintegratingOral.5 mg/1
Tablet, orally disintegratingOral1 mg/1
Tablet, orally disintegratingOral2 mg/1
Tablet, orally disintegratingOral3 mg/1
Tablet, orally disintegratingOral4 mg/1
Prices
Unit descriptionCostUnit
Risperdal consta 50 mg syr592.93USD syringe
Risperdal consta 37.5 mg syr444.68USD syringe
Risperdal consta 25 mg syr296.46USD syringe
Risperdal 1 mg/ml Solution 30ml Bottle204.42USD bottle
Risperdal M-TAB 28 1 mg Dispersible Tablet Box196.08USD box
Risperdal M-TAB 28 0.5 mg Dispersible Tablet Bottle167.82USD bottle
Risperidone 1 mg/ml Solution 30ml Bottle158.66USD bottle
Risperdal consta 12.5 mg syr148.22USD syringe
Risperdal m-tab 4 mg odt18.55USD tablet
Risperdal 4 mg tablet16.47USD tablet
Risperidone m-tab 4 mg odt15.16USD tablet
Risperdal m-tab 3 mg odt13.81USD tablet
Risperdal 3 mg tablet11.45USD tablet
Risperidone m-tab 3 mg odt11.29USD tablet
Risperdal m-tab 2 mg odt10.95USD tablet
Risperidone 4 mg tablet9.0USD tablet
Risperidone m-tab 2 mg odt8.95USD tablet
Risperdal 2 mg tablet6.94USD tablet
Risperdal m-tab 1 mg odt6.73USD tablet
Risperidone 3 mg tablet6.63USD tablet
Risperdal 1 mg tablet6.12USD tablet
Risperdal m-tab 0.5 mg odt5.76USD tablet
Risperidone 2 mg tablet5.59USD tablet
Risperidone m-tab 1 mg odt5.5USD tablet
Risperidone M-TAB 0.5 mg Dispersible Tablet4.9USD dispersible tablet
Risperidone m-tab 0.5 mg odt4.71USD tablet
Risperdal M-Tab 4 mg Disintegrating Tablet4.6USD tablet
Risperdal 0.25 mg tablet4.56USD tablet
Risperidone 0.25 mg odt4.48USD tablet
Risperdal 0.5 mg tablet3.62USD tablet
Risperdal M-Tab 3 mg Disintegrating Tablet3.44USD tablet
Risperidone 1 mg tablet3.27USD tablet
Risperidone 0.5 mg tablet3.03USD tablet
Apo-Risperidone 4 mg Tablet2.53USD tablet
Co Risperidone 4 mg Tablet2.53USD tablet
Mylan-Risperidone 4 mg Tablet2.53USD tablet
Novo-Risperidone 4 mg Tablet2.53USD tablet
Phl-Risperidone 4 mg Tablet2.53USD tablet
Pms-Risperidone 4 mg Tablet2.53USD tablet
Ran-Risperidone 4 mg Tablet2.53USD tablet
Ratio-Risperidone 4 mg Tablet2.53USD tablet
Rbx-Risperidone 4 mg Tablet2.53USD tablet
Sandoz Risperidone 4 mg Tablet2.53USD tablet
Risperdal M-Tab 2 mg Disintegrating Tablet2.29USD tablet
Apo-Risperidone 3 mg Tablet1.9USD tablet
Co Risperidone 3 mg Tablet1.9USD tablet
Mylan-Risperidone 3 mg Tablet1.9USD tablet
Novo-Risperidone 3 mg Tablet1.9USD tablet
Phl-Risperidone 3 mg Tablet1.9USD tablet
Pms-Risperidone 3 mg Tablet1.9USD tablet
Ran-Risperidone 3 mg Tablet1.9USD tablet
Ratio-Risperidone 3 mg Tablet1.9USD tablet
Rbx-Risperidone 3 mg Tablet1.9USD tablet
Sandoz Risperidone 3 mg Tablet1.9USD tablet
Risperidone 0.25 mg tablet1.88USD tablet
Apo-Risperidone 2 mg Tablet1.26USD tablet
Co Risperidone 2 mg Tablet1.26USD tablet
Mylan-Risperidone 2 mg Tablet1.26USD tablet
Novo-Risperidone 2 mg Tablet1.26USD tablet
Phl-Risperidone 2 mg Tablet1.26USD tablet
Pms-Risperidone 2 mg Tablet1.26USD tablet
Ran-Risperidone 2 mg Tablet1.26USD tablet
Ratio-Risperidone 2 mg Tablet1.26USD tablet
Rbx-Risperidone 2 mg Tablet1.26USD tablet
Sandoz Risperidone 2 mg Tablet1.26USD tablet
Risperdal M-Tab 1 mg Disintegrating Tablet1.16USD tablet
Risperdal M-Tab 0.5 mg Disintegrating Tablet0.84USD tablet
Apo-Risperidone 1 mg Tablet0.63USD tablet
Co Risperidone 1 mg Tablet0.63USD tablet
Mylan-Risperidone 1 mg Tablet0.63USD tablet
Novo-Risperidone 1 mg Tablet0.63USD tablet
Phl-Risperidone 1 mg Tablet0.63USD tablet
Pms-Risperidone 1 mg Tablet0.63USD tablet
Ran-Risperidone 1 mg Tablet0.63USD tablet
Ratio-Risperidone 1 mg Tablet0.63USD tablet
Rbx-Risperidone 1 mg Tablet0.63USD tablet
Sandoz Risperidone 1 mg Tablet0.63USD tablet
Apo-Risperidone 0.5 mg Tablet0.46USD tablet
Co Risperidone 0.5 mg Tablet0.46USD tablet
Mylan-Risperidone 0.5 mg Tablet0.46USD tablet
Novo-Risperidone 0.5 mg Tablet0.46USD tablet
Phl-Risperidone 0.5 mg Tablet0.46USD tablet
Pms-Risperidone 0.5 mg Tablet0.46USD tablet
Ran-Risperidone 0.5 mg Tablet0.46USD tablet
Ratio-Risperidone 0.5 mg Tablet0.46USD tablet
Rbx-Risperidone 0.5 mg Tablet0.46USD tablet
Sandoz Risperidone 0.5 mg Tablet0.46USD tablet
Apo-Risperidone 0.25 mg Tablet0.27USD tablet
Co Risperidone 0.25 mg Tablet0.27USD tablet
Mylan-Risperidone 0.25 mg Tablet0.27USD tablet
Novo-Risperidone 0.25 mg Tablet0.27USD tablet
Phl-Risperidone 0.25 mg Tablet0.27USD tablet
Pms-Risperidone 0.25 mg Tablet0.27USD tablet
Ran-Risperidone 0.25 mg Tablet0.27USD tablet
Ratio-Risperidone 0.25 mg Tablet0.27USD tablet
Rbx-Risperidone 0.25 mg Tablet0.27USD tablet
Sandoz Risperidone 0.25 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6110921No1993-11-192013-11-19Us
CA2406536No2009-12-222021-04-19Canada
CA2194564No1998-01-272015-07-04Canada
US6667061Yes2000-11-252020-11-25Us
US5792477Yes1997-11-022017-11-02Us
US5916598Yes1997-11-022017-11-02Us
US6379703Yes1999-06-302019-06-30Us
US6403114Yes1997-11-022017-11-02Us
US6596316Yes1999-06-302019-06-30Us
US6194006Yes1999-06-302019-06-30Us
US6224905Yes1997-12-102017-12-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)170PhysProp
boiling point (°C)442[FDA]
water solubility2.33 mg/mL[FDA]
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP3.27ALOGPS
logP2.63ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area61.94 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity114.55 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9925
Caco-2 permeable-0.5057
P-glycoprotein substrateSubstrate0.6163
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9361
Renal organic cation transporterInhibitor0.6491
CYP450 2C9 substrateNon-substrate0.8235
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.82
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8459
Ames testNon AMES toxic0.5302
CarcinogenicityNon-carcinogens0.8204
BiodegradationNot ready biodegradable0.99
Rat acute toxicity3.8290 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.65
hERG inhibition (predictor II)Inhibitor0.8062
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0000900000-b0fe7f692a00657a0970
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dl-0800900000-4e0f5ed855c5bb92c98f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-0900600000-8473cdb789508bd753a4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-3d06f3ad1210b9482139
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-d0dcf9d7f61a2c2bc652
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0000900000-dde599ea867efca2809b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900300000-9a423e6e6775ee918924
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900000000-b3a1059a8514321aac84
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900000000-3160d58bf1d154a8d21c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-2900000000-530259828e362c7f2a3c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-02u3-8900000000-c5ae8612478a7ea315c0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-9200000000-466435c830554a2d51ea
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-9100000000-352e00f2fbc78e81df2c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-9000000000-de0b42c9894812c69015
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dl-1901800000-c9a45676bc3a1d1829b7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2980000000-3574e0025348c64db6fc
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dl-0900800000-6edaf8e46040d5648f3f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0790000000-e0be2a4dba2d14313d6c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-2900000000-81e94f588db0cd3c9ea8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900300000-2ca53f2d737c37046831

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridopyrimidines
Sub Class
Not Available
Direct Parent
Pyridopyrimidines
Alternative Parents
Benzisoxazoles / Pyrimidones / Aralkylamines / Pyridines and derivatives / Piperidines / Aryl fluorides / Benzenoids / Heteroaromatic compounds / Isoxazoles / Trialkylamines
show 8 more
Substituents
Pyridopyrimidine / Benzisoxazole / Aralkylamine / Pyrimidone / Aryl fluoride / Aryl halide / Piperidine / Pyridine / Benzenoid / Pyrimidine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, pyridopyrimidine, 1,2-benzoxazoles, heteroarylpiperidine (CHEBI:8871)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  2. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  4. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E: Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res. 2006 Dec 1;148(2-3):175-83. Epub 2006 Oct 23. [PubMed:17059881]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  3. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004 Dec;7(4):461-70. Epub 2004 May 12. [PubMed:15140279]
  4. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699]
  5. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859]
  6. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
3. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
Details
4. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  3. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  4. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Details
8. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  3. Schreiber S, Backer MM, Weizman R, Pick CG: Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett. 1997 May 30;228(1):25-8. [PubMed:9197279]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Details
14. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090]
  2. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Curator comments
Acts as an inactivating antagonist competing for the ligand binding site and producing lasting inactivation of the receptor.
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971]
  2. Toohey N, Klein MT, Knight J, Smith C, Teitler M: Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol Pharmacol. 2009 Sep;76(3):552-9. doi: 10.1124/mol.109.056283. Epub 2009 Jun 9. [PubMed:19509219]
  3. Teitler M, Toohey N, Knight JA, Klein MT, Smith C: Clozapine and other competitive antagonists reactivate risperidone-inactivated h5-HT7 receptors: radioligand binding and functional evidence for GPCR homodimer protomer interactions. Psychopharmacology (Berl). 2010 Dec;212(4):687-97. doi: 10.1007/s00213-010-2001-x. Epub 2010 Sep 9. [PubMed:20827463]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600]
  2. Hendset M, Molden E, Refsum H, Hermann M: Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009 Dec;29(6):537-41. doi: 10.1097/JCP.0b013e3181c17df0. [PubMed:19910717]
  3. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987]
  4. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  8. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on July 16, 2018 21:16